Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer-Reference-Cited by-同舟云学术

Doxorubicin enhances the capacity of B cells to activate T cells in urothelial urinary bladder cancer

Published:2017-03 Issue: Volume:176 Page:63-70
ISSN:1521-6616
Container-title:Clinical Immunology
language:en
Short-container-title:Clinical Immunology

Author:

Zirakzadeh A. Ali,Kinn Johan,Krantz David,Rosenblatt Robert,Winerdal Malin E,Hu Jin,Hartana Ciputra Adijaya,Lundgren Christian,Bergman Emma Ahlén,Johansson Markus,Holmström Benny,Hansson Johan,Sidikii Alexander,Vasko Janos,Marits Per,Sherif Amir^ORCID,Winqvist Ola

Funder

Swedish Cancer Foundation

Wallenberg Foundation

Swedish Medical Research Council, Regionala forskningsrådet i Uppsala-Örebroregionen (RFR in Uppsala-Örebro)

Swedish Research Council funding for clinical research in medicine (ALF) in Västerbotten, VLL, Sweden

Cancer Research Foundation in Norrland, Umeå, Sweden

Karolinska Research Network Program in Immune Modulatory Therapies for Autoimmunity and Cancer

Publisher

Elsevier BV

Subject

Immunology,Immunology and Allergy

Reference33 articles.

1. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines;Witjes;Eur. Urol.,2014

2. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer;Grossman;N. Engl. J. Med.,2003

3. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies;Sherif;Eur. Urol.,2004

4. Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data

5. Immunological aspects of photodynamic therapy of liver tumors in a rat model for colorectal cancer;van Duijnhoven;Photochem. Photobiol.,2003

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spatial distribution of tumour immune infiltrate predicts outcomes of patients with high-risk soft tissue sarcomas after neoadjuvant chemotherapy;eBioMedicine;2024-08

2. B‐cell performance in chemotherapy: Unravelling the mystery of B‐cell therapeutic potential;Clinical and Translational Medicine;2024-07

3. Direct Immunoactivation by Chemotherapeutic Drugs in Cancer Treatment;Advanced Therapeutics;2023-09-28

4. Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity;Cells;2023-02-19

5. B cells in tumor metastasis: friend or foe?;International Journal of Biological Sciences;2023